|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of BRAF V600E and TERT coexistence in PTC was 2.1%.
|
31300059 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To elucidate the role of TERT as an eligible molecular target in these tumors, the expression of hTERT was analyzed in a series of PTCs and the effects of both pharmacological and RNA-interference-induced hTERT silencing were investigated in two human PTC cell lines (K1 and BCPAP).
|
30661164 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to determine the prevalence and clinical associations of BRAF and TERT mutations in PTC Latino patients from Colombia.
|
31454788 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation in the telomerase reverse transcriptase promoter is observed in PTC cases involving elderly male patients.
|
30788603 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that the TERT C228T mutation is significantly correlated with certain aggressive clinic-pathological features of PPTC.
|
31321667 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied 198 papillary thyroid carcinomas (PTCs), 34 follicular thyroid carcinomas (FTCs), 40 Hürthle cell carcinomas (HCCs), 14 poorly differentiated/anaplastic thyroid carcinomas (PDTC/ATC), and 15 medullary thyroid carcinomas (MTCs) for mutations in an -424 bp to +64 bp region of TERT.
|
31408918 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TERT mutation constitutes a novel genetic biomarker indicating absent or weaker <sup>131</sup> I-avid lesions in RAIR PTC patients.
|
31026111 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mechanism of the synergistic effect between BRAFV600E and TERT promoter mutations on cancer invasiveness and progression in PTC may be explained by increased TERT expression, which may result from the BRAF-induced upregulation of several ETS transcription factors.
|
30999281 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nine (69%) ATC cases with papillary thyroid carcinoma (PTC) components harboured BRAF mutations, all of which coexisted with a late mutation event (TP53, TERT, or PIK3CA).
|
31230400 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262).
|
30826992 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Associations of telomerase reverse transcriptase rs10069690 and rs2736100 polymorphisms with papillary thyroid carcinoma.
|
31651569 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that coexisting BRAF V600E and TERT mutations in patients with PTC are associated with poor initial prognostic factors and clinical course and may be useful for predicting a worse response to therapy, recurrence, and poorer outcome than in patients without the above mutations.
|
31305897 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further haplotype analysis revealed a stimulative effect of haplotypes TC and CA of TERT rs10069690-rs2736100, which increased risk for PTC in female individuals (OR = 1.579, P = 0.014; OR = 0.726, P = 0.025, respectively).
|
31538903 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas.
|
31810221 |
2019 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TERT protein overexpression was noted in 20.1% of our PTC cohort and was significantly associated with poor prognostic markers such as older age, extrathyroidal extension and Stage IV tumors.
|
29266240 |
2018 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate whether and how TERT functioned on papillary thyroid cancer (PTC) cell proliferation, the present study constructed TERT over‑expression [recombined (r)TERT plasmid group] and interference [small interfering RNA (si)‑TERT group] models by liposome transfection respectively to study the molecular mechanisms.
|
29901196 |
2018 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
|
30102829 |
2018 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared with patients harboring neither mutation, HRs (95% CIs) for PTC-specific mortality were 3.08 (0.87-10.84) for BRAF V600E alone; 8.18 (2.04-32.75) with TERT mutation alone; and 37.77 (12.50-114.09) with both mutations.
|
27581851 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT mutations were identified in 13% of adults and in none of the pediatric PTCs.
|
28176151 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For identifying telomerase reverse transcriptase promoter-mutated papillary thyroid cancer, ultrasonographic had 64.3% sensitivity, 80.8% specificity, 50.0% positive predictive value and 88.4% negative predictive value.
|
28616852 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study is to investigate if any relationship exists between the telomerase reverse transcriptase (TERT) promoter or proto-oncogene BRAF mutation and ultrasound (US) and clinicopathological features of papillary thyroid carcinomas (PTCs).
|
29312581 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The combination of BRAF and TERT promoter mutations could classify PTCs into four distinct risk groups with decreasing aggressiveness as follows: coexisting BRAF and TERT > TERT alone=BRAF alone > no mutations.
|
28666074 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, by confirming and expanding previous findings in single-institution studies, this multicenter data analysis establishes a six-genotype genetic prognostic model for poor outcomes of PTC with a risk order of genetic duet of BRAF V600E/RAS mutation and TERT mutation >BRAF V600E = TERT mutation alone >RAS mutation alone = wild-type genes.
|
27875244 |
2017 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, this study, the largest on TERT mutation so far, demonstrates a significant role of BRAF V600E and TERT promoter mutations in the aggressiveness of PTC, which is particularly robust and cooperative when the two mutations coexist.
|
26943032 |
2016 |
|
Papillary thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TERT(C228T) mutation status was an independent prognostic factor for recurrence-free survival (hazard ratio = 3.08 [confidence interval 1.042-9.079]; p = 0.042) in patients with PTC in multivariate analysis.
|
27184112 |
2016 |